Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer

Fig. 3

Rates of overall detection in the entire cohort or in specific patient subgroups. A Mutation detection rates of tumor tissue (TIS), sputum supernatant (SPU), and plasma (PLA) samples in all patients. Mutation detection rates of SPU among B patients with centrally vs. peripherally located lung tumors, C lung squamous cell carcinoma (LUSC) vs. lung adenocarcinoma (LUAD) patients, and D smokers vs. non-smokers. Comparison of detection rates of the three biopsy types in E and F patients with centrally or peripherally located lung tumors, respectively, G smokers, and I LUSC patients. Mutation detection rate was defined as the ratio of the number of samples detected with somatic mutations to the total number of samples of the same type. Numbers within the bars indicate the numbers of samples of the corresponding type, subgroup, and detection status

Back to article page